Erin O'Brien

From violence risk assessment in emergency departments to connections between bipolar disorder and substance use disorders, here are highlights from the week in Psychiatric Times.

What is new in research on psychedelics?

The investigators noted fast, clinically meaningful, and sustained improvements in symptoms of depression and related functional impairment.

The drug’s developer announced that the FDA has made 2 clarifying revisions.

An expert discusses the connections between the 2 highly comorbid diseases and some ways to effectively treat both diseases simultaneously.

From the efficacy of adjunctive TMS for treatment-resistant major depression to a look at adult ADHD, here are highlights from the week in Psychiatric Times.

What is new in research on psychiatric care for Latinx patient populations?

“Our findings might inform PTSD pathology, treatment plans, and future disaster-response strategies.”

Investigators noted sustained improvement in depressive symptoms for up to 6.5 years.

“Among employed adults with TRD, esketamine nasal spray treatment was associated with significantly larger improvements in WPL and related costs compared to quetiapine extended-release treatment.”

From cannabis use disorder and schizophrenia to social media use and youth mental health, here are highlights from the week in Psychiatric Times.

What is new in research on attention-deficit/hyperactivity disorder?

The study explored the intervention’s effects using both quantitative and qualitative methods.

The drug’s developers respond to the FDA’s decision to deny approval and consider future directions for this indication.

From new research on psilocybin as a treatment for MDD to new FDA approvals for ADHD and BED, here are highlights from the week in Psychiatric Times.

What is new in research on transcranial magnetic stimulation?

The experts weighed in on a wide variety of psychiatric issues for the August 2023 issue of Psychiatric Times.

The treatment was well-tolerated, and no serious treatment-emergent adverse effects were identified.

The funds will be distributed over the course of 5 years to support preclinical through phase 2 studies.

Generics are now approved for adults in the treatment of BED and for individuals aged 6 years and older in the treatment of ADHD.

From informed consent in treatment with psychedelics to an anti-fentanyl antibody that may reverse the signs of carfentanil overdose, here are highlights from the week in Psychiatric Times.

What is new in research on major depressive disorder?

Report reviews key study results and provides updates on additional studies in development.

“We expect this antibody to be a valuable new weapon for fighting the opioid crisis.”

Awais Aftab, MD, interviews Audrey Clare Farley, PhD, author of Girls and Their Monsters: The Genain Quadruplets and the Making of Madness in America.

Investigators also concluded that rTMS may be effective as an adjunctive treatment for patients with MDD.

The FDA did not grant approval for the treatment for major depressive disorder.

Although ulotaront was well-tolerated, results for patients treated with it were not superior to those for patients treated with placebo.

"Systemic racism is insidious and ingrained in our daily experience. Women of color are doubly minoritized."

“The described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with [Alzheimer disease].”